Although the involvement of EZH2 in the development and progression of medulloblastoma is relevant, few alterations that modify its function have been described; mutations in the functional domains that prevent methylation catalysis have been reported in other types of cancer [21,22,23,54,55,56], but its posttranscriptional regulation in medulloblastoma has not been studied. This evidence concerns the gene EZH2 and cancer.